Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 7/20 | 0.47 |
| ▸ | IL1B | P01584 | 13/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | LYN | P07948 | 1/20 | 0.32 |
| ▸ | HCK | P08631 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326810 | 0.86 | IL1B (0.54) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL26438937 | 0.86 | IL1B (0.54) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL29155893 | 0.81 | NLRP3 (0.47) | NLRP3IL1BKCNH2TNFKDR | |
| SCHEMBL29975213 | 0.81 | NLRP3 (0.47) | NLRP3IL1BKCNH2TNFKDR | |
| SCHEMBL29975535 | 0.81 | NLRP3 (0.47) | NLRP3IL1BKCNH2TNFKDR | |
| SCHEMBL29326670 | 0.80 | NLRP3 (0.54) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL29326412 | 0.79 | NLRP3 (0.48) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL29326688 | 0.78 | NLRP3 (0.48) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL29326829 | 0.77 | NLRP3 (0.51) | NLRP3IL1BKCNH2TNF | |
| SCHEMBL29326831 | 0.77 | NLRP3 (0.51) | NLRP3IL1BKCNH2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | BCDIN3D 3336/4885NLRP3 1/4885IL1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.